Status:
RECRUITING
A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lead Sponsor:
Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
This study is a multicenter, open-label, dose-finding/efficacy-expanding Phase IB/II clinical trial to evaluate SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with l...
Eligibility Criteria
Inclusion
- Subjects are able to give voluntary informed consent, understand the study and are willing to follow and complete all the test procedures.
- Age 18\~70 years old.
- Pathologically confirmed unresectable locally advanced/metastatic non-small cell lung cancer.
- At least one measurable lesion per RECIST v1.1 criteria.
- ECOG PS score: 0-1.
Exclusion
- Active or symptomatic brain metastases.
- Previous diagnosis of any other malignancy.
- Clinically symptomatic moderate to severe ascites; Uncontrollable or moderate or above pleural effusion, pericardial effusion.
- Received anti-tumor therapy 4 weeks prior to initiation of study treatment.
- Uncontrolled tumor-related pain.
- Subjects with severe cardiovascular and cerebrovascular diseases.
Key Trial Info
Start Date :
September 27 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2026
Estimated Enrollment :
124 Patients enrolled
Trial Details
Trial ID
NCT06589778
Start Date
September 27 2024
End Date
April 30 2026
Last Update
November 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China, 200030